| ABLYNX NV Patent applications |
| Patent application number | Title | Published |
|---|
| 20120128669 | MONOVALENT, BIVALENT AND TRIVALENT ANTI HUMAN RESPIRATORY SYNCYTIAL VIRUS (HRSV) NANOBODY CONSTRUCTS FOR THE PREVENTION AND/OR TREATMENT OF RESPIRATORY TRACT INFECTIONS - Amino acid sequences are provided that are directed against and/or that can specifically bind protein F of hRSV, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The amino acid sequences, polypeptides and therapeutic compounds and compositions provided by the invention show an improved stability, less immunogenicity and/or improved affinity and/or avidity for protein F of hRSV. The invention also relates to the uses of such amino acid sequences, polypeptides, compounds or constructs for prophylactic and/or therapeutic purposes. | 05-24-2012 |
| 20120093839 | NOVEL ANTIGEN BINDING DIMER-COMPLEXES, METHODS OF MAKING/AVOIDING AND USES THEREOF - In a broad aspect the present invention generally relates to novel dimer-complexes (herein called “non-fused-dimers” or NFDs) comprising single variable domains, methods of making these complexes and uses thereof. These non-covalently bound dimer-complexes consist of two identical monomers that each comprises of one or more single variable domains (homodimers) or of two different monomers that each comprises on or more single variable domains (heterodimers). The subject NFDs have typically altered e.g. improved binding characteristics over their monomelic counterpart. The NFDs of the invention may further be engineered through linkage by a flexible peptide or cysteines in order to improve the stability. This invention also describes conditions under which such NFDs are formed and conditions under which the formation of such dimers can be avoided. | 04-19-2012 |
| 20120077731 | AMINO ACID SEQUENCES DIRECTED AGAINST IL-6R AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF IL-6R RELATED DISEASES AND DISORDERS - The present invention relates to amino acid sequences that are directed against/and or that can specifically bind Interleukin-6 Receptor (IL-6R) with improved affinity and/or avidity, and/or that have an improved efficacy and/or potency, and which are capable of (partially, or preferably totally) blocking the IL-6/IL-6R interaction and/or inhibit signalization through IL-6, 1L-6R and/or the IL-6/IL-6R complex. The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid sequences and polypeptides, to methods for preparing such amino acid sequences and polypeptides, to host cells expressing or capable of expressing such amino acid sequences or polypeptides, to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells, and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes. | 03-29-2012 |
| 20120076796 | AMINO ACID SEQUENCES DIRECTED AGAINST THE ANGIOPOIETIN/TIE SYSTEM AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF DISEASES AND DISORDERS RELATED TO ANGIOGENESIS - The present invention relates to amino acid sequences that are directed against proteins from the group of the Angiopoietin/Tie family such as Tie1, Tie2, Ang1, Ang2, Ang3, Ang4, Angptl1, Angptl12, Angptl13, Angptl14, Angptl15, Angptl16, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more of such amino acid sequences. | 03-29-2012 |
| 20120039870 | BINDING MOLECULES WITH MULTIPLE BINDING SITES, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF - The present invention relates to binding molecules, such as amino acid sequences with multiple antigen binding sites. In particular, the binding molecules of the present invention have at least two antigen binding sites that partially or fully overlap with each other and that are directed against at least two different naturally occurring binding molecules. The invention further relates to uses of such binders, for example in methods for inhibiting and/or blocking of the interaction between said at least two naturally occurring binding molecules and a third naturally occurring binding molecule. | 02-16-2012 |
| 20110318366 | BIOLOGIC COMPOUNDS - The present invention relates to amino acid sequences that are directed against TRAIL cell surface receptor 2 (herein also “DR5”), as well as to compounds or constructs thereof, and in particular proteins and polypeptides and nucleotides that encode them (referred to herein in their entirety as “NB agents”) and fragments thereof, and pharmaceutically effective variants thereof, and their use in the diagnosis and treatment of DR5 associated diseases and disorders. | 12-29-2011 |
| 20110318347 | AMINO ACID SEQUENCES TARGETING HUMAN CD4, CXCR4, CCR5, TLR4, ALPHAV INTEGRIN, BETA3-INTEGRIN, BETA1-INTEGRIN, HUMAN ALPHA2-INTEGRIN, CD81, SR-BI, CLAUDIN-1, CLAUDIN-6 AND CLAUDIN-9, RESPECTIVELY, AND NEUTRALIZING VIRAL ENTRY - The present invention relates to amino acid sequences that are directed against (as defined herein) human cellular receptors for viruses and/or bacteria such as e.g. Nanobodies specifically recognizing hCD4, hCXCR4, hCCR5. hTLR4, human alphaV integrin, human beta3 integrin, human beta1 integrin, human alpha2 integrin, hCD81, hSR-B1, hClaudin-1, hClaudin-6 and hClaudin-9, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. Said amino acid sequences may be used to prevent human cell entry of HIV, HCV, adenoviruses, hantavirus, herpesvirus, echo-virus 1 and others. | 12-29-2011 |
| 20110311515 | PULMONARY ADMINISTRATION OF IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS AND CONSTRUCTS THEREOF - The present invention relates to a method wherein an immunoglobulin single variable domain (such as a Nanobody) and/or construct thereof are absorbed in pulmonary tissue. More particularly, the invention provides systemic delivery of an immunoglobulin single variable domain and/or construct thereof via the pulmonary route. | 12-22-2011 |
| 20110294982 | AMINO ACID SEQUENCES DIRECTED AGAINST INTEGRINS AND USES THEREOF - The present invention relates to amino acid sequences that are directed against (as defined herein) Integrins, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences (also referred to herein as | 12-01-2011 |
| 20110293603 | AMINO ACID SEQUENCES DIRECTED AGAINST MULTITARGET SCAVENGER RECEPTORS AND POLYPEPTIDES - The present invention relates to amino acid sequences that are directed against (as defined herein) multitarget scavenger receptors such as e.g. Lox-1, RAGE, CD36, SR-A1, SR-B1, galectin-1, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences (also referred to herein as “amino acid sequences of the invention”, “compounds of the invention”, and “polypeptides of the invention”, respectively). | 12-01-2011 |
| 20110282033 | AMINO ACID SEQUENCES DIRECTED AGAINST GROWTH FACTOR RECEPTORS AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH GROWTH FACTORS AND THEIR RECEPTORS - The present invention relates to amino acid sequences that are directed against receptors for growth factors, compounds comprising such sequences, as well as nucleic acid sequences encoding the same. In one embodiment the invention relates to amino acid sequences that bind to a receptor tyrosine kinase. The receptor tyrosine kinase and/or growth factor receptor may be of human origin. In one embodiment the amino acid sequences are Nanobodies™. | 11-17-2011 |
| 20110262438 | BIOLOGICAL MATERIALS RELATED TO CXCR7 - The present invention relates to particular polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. | 10-27-2011 |
| 20110262427 | AMINO ACID SEQUENCES THAT MODULATE THE INTERACTION BETWEEN CELLS OF THE IMMUNE SYSTEM - The present invention relates to amino acid sequences that block the interaction between (a target on) an antigen presenting cell (APC) and (a target on) a T-cell. More particularly, the present invention relates to amino acid sequences that are directed against (as defined herein) a target on an APC (also referred to herein as “APC target”) or a target on a T-cell (also referred to herein as “T-cell target”). The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. | 10-27-2011 |
| 20110243954 | PEPTIDES CAPABLE OF BINDING TO SERUM PROTEINS AND COMPOUNDS, CONSTRUCTS AND POLYPEPTIDES COMPRISING THE SAME - Provided are pharmaceutical compositions, preparations or formulations including a compounds or constructs that include at least one amino acid sequence that is directed against serum albumin and at least one therapeutic moiety. The pharmaceutical compositions, preparations or formulations are preparations or formulations that are suitable for and/or intended for, e.g., pulmonary administration. Methods for use of the pharmaceutical compositions, preparations or formulations also are provided. | 10-06-2011 |
| 20110206660 | AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRS AND COMPOUNDS COMPRISING THE SAME - The present invention relates to amino acid sequences that are directed against (as defined herein) G-protein coupled receptors (GPCRs) and in particular to CXCR4 and CXCR7, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences (also referred to herein as “amino acid sequences of the invention”, “compounds of the invention”, and “polypeptides of the invention”, respectively). Furthermore, the invention provides a new method of making amino acid sequences that are directed against transmembrane protein, and in particular for multiple spanning transmembrane proteins for which the native conformation cannot be reproduced in other “in vitro” system (e.g. GPCRs in general). | 08-25-2011 |
| 20110189203 | IMMUNOGLOBULIN CONSTRUCTS - The present invention relates to protein and polypeptide constructs that comprise single variable domains that are linked to an Fc portion. The immunoglobulin constructs comprise two polypeptide chains in which each polypeptide chain comprises two or more single variable domains that are linked, usually via a suitable hinge region or linker, to one or more constant domains that, together, form an Fc portion. The invention also relates to polypeptide chains that form part of such constructs and/or that can be used to form such constructs. The invention further relates to nucleotide sequences and nucleic acids that encode or can be used to express such constructs or polypeptide chains; to methods for producing such constructs and polypeptides chains; to compositions (and in particular pharmaceutical compositions) that comprise such constructs or polypeptide chains; and to uses of such constructs, polypeptide chains or compositions. | 08-04-2011 |
| 20110184151 | SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREFOR - The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to Epidermal Growth Factor Receptor. It further relates to single domain antibodies that are Camelidae VHHs. It further relates to methods of administering said polypeptides orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation. It further relates to protocols for screening for agents that modulate the Epidermal Growth Factor Receptor, and the agents resulting from said screening. The invention further a method for delivering therapeutic molecules to the interior of cells. | 07-28-2011 |
| 20110184150 | SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST TUMOR NECROSIS FACTOR-ALPHA AND USES THEREFOR - The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to Tumor Necrosis Factor-alpha. It further relates to single domain antibodies that are Camelidae VHHs. It further relates to methods of administering said polypeptides. It further relates to protocols for screening for agents that modulate the TNF-alpha receptor, and the agents resulting from said screening. | 07-28-2011 |
| 20110184145 | METHOD OF ADMINISTERING THERAPEUTIC POLYPEPTIDES, AND POLYPEPTIDES THEREFOR - The invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further a method for delivering therapeutic molecules to the interior of cells. The invention further relates to anti-IgE therapeutic molecules. | 07-28-2011 |
| 20110178277 | STABILIZED SINGLE DOMAIN ANTIBODIES - The present invention relates to heterospecific polypeptide constructs comprising at least one single domain antibody directed against a therapeutic and/or diagnostic target and at least one single domain antibody directed against a serum protein, said construct having a prolonged lifetime in biological circulatory systems. The invention further relates to methods for stabilising VHHs in biological circulatory systems. | 07-21-2011 |
| 20110158996 | VON WILLEBRAND FACTOR SPECIFIC BINDERS AND METHODS OF USE THEREFOR - The invention provides new uses for specific binders to the Al domain of the von Willebrand Factor (vWF), in particular the use in patients with stable angina undergoing elective percutaneous coronary intervention. Furthermore, dosing schedules and use of suitable assays such as RIPA and RICO in the particular disease settings are provided. | 06-30-2011 |
| 20110129458 | BINDING MOLECULES WITH MULTIPLE BINDING SITES, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF - The present invention relates to binding molecules, such as amino acid sequences with multiple antigen binding sites. In particular, the binding molecules of the present invention have at least two antigen binding sites that partially or fully overlap with each other and that are directed against at least two different naturally occurring binding molecules. The invention further relates to uses of such binders, for example in methods for inhibiting and/or blocking of the interaction between said at least two naturally occurring binding molecules and a third naturally occurring binding molecule. | 06-02-2011 |
| 20110123529 | SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREFOR - The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to Epidermal Growth Factor Receptor. It further relates to single domain antibodies that are Camelidae VHHs. It further relates to methods of administering said polypeptides orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation. It further relates to protocols for screening for agents that modulate the Epidermal Growth Factor Receptor, and the agents resulting from said screening. The invention further a method for delivering therapeutic molecules to the interior of cells. | 05-26-2011 |
| 20110118185 | AMINO ACID SEQUENCES DIRECTED AGAINST VASCULAR ENDOTHELIAL GROWTH FACTOR AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF CONDITIONS AND DISEASES CHARACTERIZED BY EXCESSIVE AND/OR PATHOLOGICAL ANGIOGENESIS OR NEOVASCULARIZATION - The present invention relates to amino acid sequences that are directed against vascular endothelial growth factor (VEGF), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The amino acid sequences, compounds and constructs can be used for prophylactic, therapeutic or diagnostic purposes, such as for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization. | 05-19-2011 |
| 20110105733 | SINGLE VARIABLE DOMAINS AGAINST THE NOTCH PATHWAYS - The present invention relates to amino acid sequences (also referred to herein as “single variable domain(s) of the invention”. “Nanobody™ of the invention” or “Nanobodies™ of the invention”, ilpolypeptide(s) of the invention”) that are directed against (as defined herein) members of the Notch signalling pathway such as the four mammalian members of the Notch Receptors (Notch-1, Notch-2, Notch-3, Notch-4, hereinafter also “Notch Receptors”) and the five mammalian members of the Notch Ligands (the Delta-like family with “DLL1”, “DLL3”, “DLL4” wherein “DLL” stands for Delta-like ligand; the Jagged family with “Jagged-1”, “Jagged-2”, hereinafter also “Notch Ligands”), as well as to constructs that comprise or essentially consist of one or more such single variable domain(s) (also referred to herein as “construct of the invention” and “constructs of the invention”, “Nanobody™ of the invention” or “Nanobodies™ of the invention”, respectively). In particular, this invention relates to Notch pathway interfering single variable domains down- or up-regulating Notch signaling (also referred to herein “Notch-antagonists” or “Notch-agonists”). | 05-05-2011 |
| 20110091462 | NOVEL ANTIGEN BINDING DIMER-COMPLEXES, METHODS OF MAKING AND USES THEREOF - In a broad aspect the present invention generally relates to novel dimer-complexes (herein called “non-fused-dimers” or NFDs) comprising single variable domains, methods of making these complexes and uses thereof. These non-covalently bound dimer-complexes consist of two identical monomers that each comprises of one or more single variable domains (homodimers) or of two different monomers that each comprises on or more single variable domains (heterodimers). The subject NFDs have typically altered e.g. improved binding characteristics over their monomeric counterpart. The NFDs of the invention may further be engineered through linkage by a flexible peptide or cysteines in order to improve the stability. This invention also describes conditions under which such NFDs are formed and conditions under which the formation of such dimers can be avoided. | 04-21-2011 |
| 20110059101 | Amino Acid Sequences Directed Against Il-6 And Polypetides Comprising The Same For The Treatment Of Diseases And Disorders Associated With Il-6 Mediated Signalling - The present invention relates to amino acid sequences that are directed against interleukin-6 (IL-6), as well as to compounds or constructs, and in particular proteins and polypeptides that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid sequences and polypeptides to methods for preparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences, polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes. | 03-10-2011 |
| 20110059090 | AMINO ACID SEQUENCES DIRECTED AGAINST HER2 AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF CANCERS AND/OR TUMORS - The present invention relates to amino acid sequences and Nanobodies that are directed against Epidermal Growth Factor Receptor 2 (HER2), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. | 03-10-2011 |
| 20110053865 | AMINO ACID SEQUENCES DIRECTED AGAINST HETERODIMERIC CYTOKINES AND/OR THEIR RECEPTORS AND POLYPEPTIDES COMPRISING THE SAME - The present invention relates to amino acid sequences that are directed against (at defined herein) heterodimeric cytokines and/or their receptors, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consists of one or more such amino acid sequences ( also referred to herein as “amino acid sequences of the invention”, “compounds of the invention”, and “polypeptides of the invention”, respectively). The invention also relates to nucleic acids encoding such amino acid sequences and polypeptides (also referred to herein as “nucleic acids of the invention” or “nucleotides sequences of the invention”); to methods for preparing such amino acid sequences and polypeptides; to hose cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that complete such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes, such as the prophylactic, therapeutic or diagnostic purposes mentioned herein. | 03-03-2011 |
| 20110027281 | SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST TUMOR NECROSIS FACTOR-ALPHA AND USES THEREFOR - The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to Tumor Necrosis Factor-alpha. It further relates to single domain antibodies that are Camelidae VHHs. It further relates to methods of administering said polypeptides. It further relates to protocols for screening for agents that modulate the TNF-alpha receptor, and the agents resulting from said screening. | 02-03-2011 |
| 20110021980 | NEEDLE-FREE DELIVERY DEVICE FOR THERAPEUTIC PROTEINS BASED ON SINGLE ANTIGEN-BINDING DOMAINS SUCH AS NANOBODIES.RTM. - The present invention relates to needle-free delivery devices for administering therapeutic or diagnostic therapeutic proteins that are based on single domain antibodies, and methods of using such a device in therapies or diagnostic applications. | 01-27-2011 |
| 20110002929 | AMINO ACID SEQUENCES DIRECTED AGAINST RANK-L AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF BONE DISEASES AND DISORDERS - The present invention relates to amino acid sequences that are directed against RANK-L, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid sequences and polypeptides; to methods for preparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes. | 01-06-2011 |
| 20100330084 | SINGLE DOMAIN VHH ANTIBODIES AGAINST VON WILLEBRAND FACTOR - The present invention relates to improved Nanobodies™ against von Willebrand Factor (vWF), as well as to polypeptides comprising or essentially consisting of one or more of such Nanobodies. The invention also relates to nucleic acids encoding such Nanobodies and polypeptides; to methods for preparing such Nanobodies and polypeptides; to host cells expressing or capable of expressing such Nanobodies or polypeptides; to compositions comprising such Nanobodies, polypeptides, nucleic acids or host cells; and to uses of such Nanobodies, such polypeptides, such nucleic acids, such host cells or such compositions, in particular for prophylactic, therapeutic or diagnostic purposes, such as the prophylactic, therapeutic or diagnostic purposes. | 12-30-2010 |
| 20100226920 | MEDICAL DELIVERY DEVICE FOR THERAPEUTIC PROTEINS BASED ON SINGLE DOMAIN ANTIBODIES - The present invention relates to a pen-style administration device for administering therapeutic or diagnostic therapeutic proteins that are based on single domain antibodies, and methods of using such a device in therapies or diagnoses. | 09-09-2010 |
| 20100216187 | AMINO ACID SEQUENCES THAT BIND TO A DESIRED MOLECULE IN A CONDITIONAL MANNER - The present invention relates to amino acid sequences that bind to serum proteins such as serum albumin; to compounds, proteins and polypeptides comprising or essentially consisting of such amino acid sequences; to nucleic acids that encode such amino acid sequences, proteins or polypeptides; to compositions, and in particular pharmaceutical compositions, that comprise such amino acid sequences, proteins and polypeptides; and to uses of such amino acid sequences, proteins and polypeptides, is essentially conditional on different physiological situations, e.g. is different under acidic condition than under pH-neutral condition. | 08-26-2010 |
| 20100215664 | AMINO ACID SEQUENCES DIRECTED AGAINST IL-6R AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH IL-6 -MEDIATED SIGNALLING - The invention relates to amino acid sequences that are directed against and/or that can specifically bind to IL-6 receptor, compounds or constructs that comprise said amino acid sequence, nucleic acids that encode said amino acid sequences, compounds or constructs, pharmaceutical compositions comprising said amino acid sequences, compounds or constructs as well as methods for the prevention and/or treatment of diseases and disorders associated with IL-6 receptor. | 08-26-2010 |
| 20100173799 | METHOD FOR GENERATION OF IMMUNOGLOBULIN SEQUENCES - The present invention relates to a method for generating immunoglobulin sequences against cell-associated antigens, more particularly, antigens that are membrane-anchored. The invention also provides immunoglobulin sequences obtainable by the method of the invention. Specifically, the present invention relates to the generation of immunoglobulin sequences by use of DNA vaccination. More specifically, the present invention relates to generation of immunoglobulin sequences in camelids, preferably directed against cell-associated antigens, in particular antigens with multiple transmembrane spanning domains, including GPCRs and ion channels, by DNA vaccination. Furthermore, the present invention relates to said immunoglobulin sequences against cell-associated antigens, more particularly, antigens that are membrane-anchored, such as e.g. GPCRs and ion channels, more preferably ion channels. | 07-08-2010 |
| 20100150939 | AMINO ACID SEQUENCES DIRECTED AGAINST A METALLOPROTEINASE FROM THE ADAM FAMILY AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF ADAM-RELATED DISEASES AND DISORDERS - The present application relates to amino acid sequences that are directed against and/or that can specifically bind to metalloproteinases from the ADAM family, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such ammo acid sequences, and to methods of preparing the same. | 06-17-2010 |
| 20100136018 | Anti-FC-receptor single domain antibodies (nanobodies-tm) and therapeutic use - The present invention relates to amino acid sequences that are directed against (as defined herein) receptors for proteins with an immunoglobulin fold (Fc receptors), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid sequences and polypeptides; to methods for preparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic puiposes, such as the prophylactic, therapeutic or diagnostic purposes mentioned herein. | 06-03-2010 |
| 20100129368 | Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the pH, compounds comprising the same, and uses thereof - The present invention relates to amino acid sequences that binding to serum proteins such as serum albumin; to compounds, proteins and polypeptides comprising or essentially consisting of such amino acid sequences; to nucleic acids that encode such amino acid sequences, proteins or polypeptides; to compositions, and in particular pharmaceutical compositions, that comprise such amino acid sequences, proteins and polypeptides; and to uses of such amino acid sequences, proteins and polypeptides, is essentially independent in the pH range 5 to 8. | 05-27-2010 |
| 20100129354 | INTRANASAL DELIVERY OF POLYPEPTIDES AND PROTEINS - The present invention relates to the intranasal delivery of therapeutic polypeptides and proteins comprising a Nanobody®, a domain antibody, a single domain antibody or a “dAb”. The present invention provides compositions comprising a therapeutically effective amount of such polypeptide or protein and further comprising a pharmaceutically acceptable nasal carrier. The invention also relates to methods for the treatment of a subject comprising the delivery of said polypeptides and proteins to said subject by the nasal route. | 05-27-2010 |
| 20100120681 | AMINO ACID SEQUENCES DIRECTED AGAINST VASCULAR ENDOTHELIAL GROWTH FACTOR AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF CONDITIONS AND DISEASES CHARACTERIZED BY EXCESSIVE AND/OR PATHOLOGICAL ANGIOGENESIS OR NEOVASCULARIZATION - The present invention relates to amino acid sequences that are directed against vascular endothelial growth factor (VEGF), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The amino acid sequences, compounds and constructs can be used for prophylactic, therapeutic or diagnostic purposes, such as for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization. | 05-13-2010 |
| 20100104568 | AMINO ACID SEQUENCES DIRECTED AGAINST RANK-L AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF BONE DISEASES AND DISORDERS - The present invention relates to amino acid sequences that are directed against RANK-L, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid sequences and polypeptides; to methods for preparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes. | 04-29-2010 |
| 20100092460 | AMINO ACID SEQUENCES DIRECTED AGAINST CHEMOKINES AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF CHEMOKINE-RELATED DISEASES AND DISORDERS - The present invention relates to amino acid sequences that are directed against chemokines, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid sequences and polypeptides; to methods for preparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes. | 04-15-2010 |
| 20100062004 | AMINO ACID SEQUENCES DIRECTED AGAINST GPCRS AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF GPCR-RELATED DISEASES AND DISORDERS - The present invention relates to amino acid sequences that are directed G-protein coupled receptors (GPCRs), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid sequences and polypeptides to methods for preparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes, such as the prophylactic, therapeutic or diagnostic purposes mentioned herein. | 03-11-2010 |
| 20100040613 | POLYPEPTIDE CONSTRUCTS FOR SUBLINGUAL ADMINISTRATION - The invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further a method for delivering therapeutic molecules to the interior of cells. The invention further relates to anti-IgE therapeutic molecules. | 02-18-2010 |
| 20100028341 | AMINO ACID SEQUENCES THAT MODULATE THE INTERACTION BETWEEN CELLS OF THE IMMUNE SYSTEM - The present invention relates to amino acid sequences that block the interaction between (a target on) an antigen presenting cell (APC) and (a target on) a T-cell. More particularly, the present invention relates to amino acid sequences that are directed against (as defined herein) a target on an APC (also referred to herein as “APC target”) or a target on a T-cell (also referred to herein as “T-cell target”). The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences | 02-04-2010 |
| 20100022452 | Nanobodies for the treatment of aggregation-mediated disorders - The present invention relates to improved Nanobodies™ against von Willebrand Factor (vWF), as well as to polypeptides comprising or essentially consisting of one or more of such Nanobodies. The invention also relates to nucleic acids encoding such Nanobodies and polypeptides; to methods for preparing such Nanobodies and polypeptides; to host cells expressing or capable of expressing such Nanobodies or polypeptides; to compositions comprising such Nanobodies, polypeptides, nucleic acids or host cells; and to uses of such Nanobodies, such polypeptides, such nucleic acids, such host cells or such compositions, in particular for prophylactic, therapeutic or diagnostic purposes, such as the prophylactic, therapeutic or diagnostic purposes. | 01-28-2010 |
| 20100021459 | POLYPEPTIDE CONSTRUCTS FOR INTRACELLULAR DELIVERY - The invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further a method for delivering therapeutic molecules to the interior of cells. The invention further relates to anti-IgE therapeutic molecules. | 01-28-2010 |
| 20100003253 | SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREFOR - The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to Epidermal Growth Factor Receptor. It further relates to single domain antibodies that are | 01-07-2010 |
| 20100003249 | POLYPEPTIDE CONSTRUCTS FOR TOPICAL ADMINISTRATION - The invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further a method for delivering therapeutic molecules to the interior of cells. The invention further relates to anti-IgE therapeutic molecules. | 01-07-2010 |
| 20100003248 | POLYPEPTIDE CONSTRUCTS FOR RECTAL AND/OR VAGINAL ADMINISTRATION - The invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further a method for delivering therapeutic molecules to the interior of cells. The invention further relates to anti-IgE therapeutic molecules. | 01-07-2010 |
| 20090324512 | POLYPEPTIDE CONSTRUCTS FOR NASAL ADMINISTRATION - The invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further a method for delivering therapeutic molecules to the interior of cells. The invention further relates to anti-IgE therapeutic molecules. | 12-31-2009 |
| 20090297535 | Amino Acid Sequences Directed Against Il-6 And Polypetides Comprising The Same For The Treatment Of Diseases And Disorders Associated With Il-6 Mediated Signalling - The present invention relates to amino acid sequences that are directed against interleukin-6 (IL-6), as well as to compounds or constructs, and in particular proteins and polypeptides that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid sequences and polypeptides to methods for preparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences, polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes. | 12-03-2009 |
| 20090286727 | DP-78-Like Nanobodies - The present invention relates to Nanobodies® that have a high degree of sequence homology with human variable domain sequences from the V | 11-19-2009 |
| 20090281277 | PEPTIDES CAPABLE OF BINDING TO SERUM PROTEINS AND COMPOUNDS, CONSTRUCTS AND POLYPEPTIDES COMPRISING THE SAME - The present invention relates to amino acid sequences that are capable of binding to serum proteins; to compounds, proteins, polypeptides, fusion proteins or constructs comprising or essentially consisting of such amino acid sequences; to nucleic acids that encode such amino acid sequences, compounds, proteins, polypeptides, fusion proteins or constructs; to compositions, and in particular pharmaceutical compositions, that comprise such amino acid sequences, compounds, proteins, polypeptides, fusion proteins or constructs; and to uses of such amino acid sequences, compounds, proteins, polypeptides, fusion proteins or constructs. | 11-12-2009 |
| 20090252681 | Nanobodies and Polypeptides Against EGFR and IGF-IR - The invention relates to polypeptides and Nanobodies against Epidermal Growth Factor Receptor (EGFR) and/or Insulin Growth Factor-I Receptor (IGF-IR). The invention also relates to nucleic acids encoding such Nanobodies and polypeptides; to methods for preparing such Nanobodies and polypeptides; to host cells expressing or capable of expressing such Nanobodies or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such Nanobodies, polypeptides, nucleic acids and/or host cells; and to uses of such Nanobodies, polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes. | 10-08-2009 |
| 20090238829 | Stabilized single domain antibodies - The present invention relates to heterospecific polypeptide constructs comprising at least one single domain antibody directed against a therapeutic and/or diagnostic target and at least one single domain antibody directed against a serum protein, said construct having a prolonged lifetime in biological circulatory systems. The invention further relates to methods for stabilising VHHs in biological circulatory systems. | 09-24-2009 |
| 20090074770 | Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the pH, compounds comprising the same, and uses thereof - The present invention relates to amino acid sequences that binding to serum proteins such as serum albumin; to compounds, proteins and polypeptides comprising or essentially consisting of such amino acid sequences; to nucleic acids that encode such amino acid sequences, proteins or polypeptides; to compositions, and in particular pharmaceutical compositions, that comprise such amino acid sequences, proteins and polypeptides; and to uses of such amino acid sequences, proteins and polypeptides, is essentially independent in the pH range 5 to 8. | 03-19-2009 |
| 20090028880 | Serum albumin binding proteins - The present invention relates to amino acid sequences that are capable of binding to serum albumin, which sequences do not significantly reduce or inhibit the binding of serum albumin to FcRn or significantly reduce the half-life of serum albumin. It further relates to proteins and polypeptides comprising or essentially consisting of such amino acid sequences; to nucleic acids that encode such amino acid sequences, proteins or polypeptides; to compositions, and in particular pharmaceutical compositions, that comprise such amino acid sequences, proteins and polypeptides; and to uses of such amino acid sequences, proteins and polypeptides. | 01-29-2009 |
| 20090022721 | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor - The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to Tumor Necrosis Factor-alpha. It further relates to single domain antibodies that are Camelidae VHHs. It further relates to methods of administering said polypeptides. It further relates to protocols for screening for agents that modulate the TNF-alpha receptor, and the agents resulting from said screening. | 01-22-2009 |
| 20080267949 | Peptides capable of binding to serum proteins - The present invention relates to amino acid sequences that are capable of binding to serum proteins; to compounds, proteins, polypeptides, fusion proteins or constructs comprising or essentially consisting of such amino acid sequences; to nucleic acids that encode such amino acid sequences, compounds, proteins, polypeptides, fusion proteins or constructs; to compositions, and in particular pharmaceutical compositions, that comprise such amino acid sequences, compounds, proteins, polypeptides, fusion proteins or constructs; and to uses of such amino acid sequences, compounds, proteins, polypeptides, fusion proteins or constructs. | 10-30-2008 |
